Cannabis Law Report

AUGUST 24, 2021

Nasdaq:HUGE) (CSE:HUGE) (FRA:0K9) (the “ Company ” or “ FSD ”) announced today that it intends to terminate the Phase 2 clinical trial of ultra-micronized palmitoylethanolamide (“PEA”), or FSD-201, for use in treating COVID-19. TORONTO–(BUSINESS WIRE)–FSD Pharma Inc.

Clinical Trials 105

Clinical Trials Treatment Pharmaceutical Concentrates 105

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

JULY 19, 2021

There is an urgent need for objective, scientifically sound and robust clinical trials to support medicinal cannabis and psychedelics (psilocybin, MDMA, LSD, Ketamine). Extensive early phase experience with appropriate safety oversight and early phase clinic.

Clinical Trials 98

Clinical Trials Research and Development Hybrid Medicine 98

Cannabis Law Report

AUGUST 23, 2021

Phase I clinical trial of the Satipharm CBD capsules in which results demonstrated the safety and high performance of the oral capsule technology, including the superior delivery profile of cannabidiol (CBD) compound to trial subjects. The treatment was generally well tolerated and the median reduction in seizures was 81.9%

Clinical Trials 105

Clinical Trials CBD Epilepsy Treatment 105

Veriheal

AUGUST 22, 2022

Clinical trials into cannabis’ potential as an opioid replacement are well underway in South Africa. ” Dr. Gallow prides himself on his work as a South African cannabis advocate and leader in the international medical cannabis research field. About the Opioid Epidemic.

Clinical Trials 111

Clinical Trials Chronic Pain Hydroponic Strains 111

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

AUGUST 22, 2021

Silo Pharma’s notice of allowance paves the way toward clinical trials for its psychedelics delivery platform using homing peptides. Unlike competitors administering generic psychedelics, the company’s patented technology could improve safety and efficacy while guaranteeing market exclusivity. Silo Pharma Inc. Silo Pharma Inc.

Clinical Trials 105

Clinical Trials Research and Development Safety Treatment 105

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. Studies have suggested that CBD may help manage chronic pain, reduce anxiety and depression, alleviate symptoms of epilepsy, and even aid in cancer treatment.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

The Cannigma

OCTOBER 11, 2021

Published in Cannabis and Cannabinoid Research in late September, the survey found that the majority of respondents reported that their health conditions were “very much improved” or “much improved” by the use of CBG. No clinical trial was used in the compilation of the study. who have used it to treat anxiety.

Conditions 132

Conditions Clinical Trials Chronic Pain Cannabinoids 132

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 92

Clinical Trials Research and Development Therapy Policy 92

Canna Care Docs

OCTOBER 3, 2023

Conventional medication methods such as opiates may help terminal patients focus on more palliative treatment options and goals in order to better one’s comfort and overall quality of life during this time. However, many of these pharmaceutical medications can just induce more unpleasant, debilitating effects on those who are ill.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Medicinal Marijuana Association

FEBRUARY 11, 2024

You may have heard whispers of cannabis being used to address a specific eye condition, but what does the research truly reveal about its effectiveness? The potential link between cannabis and glaucoma treatment is a topic of ongoing investigation, stirring both curiosity and caution within the medical community.

Treatment 52

Treatment Blood Pressure Conditions Clinical Trials 52

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Eight studies were included, all of which are randomized controlled trials. 1.69, 95% CI [1.20–2.36])

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

JUNE 21, 2021

In the medical cannabis industry, mostly due to the plant’s long history of prohibition, there is a decided lack of data regarding the use and efficacy of cannabis as a treatment for a wide variety of indications. The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. June 14, 2022 02:00 AM Eastern Daylight Time.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Cannabis Law Report

JULY 13, 2022

Their position as therapeutic practitioners, as well as their work in conducting the kind of clinical trials necessary to advance regulatory outcomes for psychedelic medicines, make them ideal partners in alignment with Optimi’s strategic goals.”. VANCOUVER, British Columbia, July 13, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (

Therapy 52

Therapy Clinical Trials Microdosing Research and Development 52

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

The Cannigma

FEBRUARY 2, 2021

This article was originally published on Analytical Cannabis and appears here with permission. . In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

PrestoDoctor

OCTOBER 11, 2023

For years, the use of cannabis has been a controversial topic. One area of research that has been gaining attention is the use of CBD-rich cannabis in treating the social symptoms of Autism Spectrum Disorder (ASD). One such area of focus is the use of CBD-rich cannabis. What is CBD?

CBD 52

CBD Research and Development Clinical Trials Treatment 52

Canna Law Blog

NOVEMBER 15, 2021

There was a fascinating panel on the use of ketamine treatments for, among other things, depression and anxiety disorders. We continue to see an uptick in ketamine clinic transactions (the complexities of which we have written about extensively ). Pharmaceutical start-ups are betting on the treatment potential of psychedelics.

Clinical Trials 98

Clinical Trials Treatment Microdosing Pharmaceutical 98

MMJ Recs

NOVEMBER 20, 2023

This article delves into the science behind medical marijuana, focusing on cannabinoids, the active compounds found in the cannabis plant, and their remarkable therapeutic effects. THC is the primary psychoactive compound in cannabis, responsible for the “high” or euphoric feeling associated with marijuana use.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

TheAnswerPage

FEBRUARY 23, 2022

Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). What are the common adverse events noted in clinical trials examining the efficacy of cannabinoids for ASD? Fletcher S. Child: care, health and development. 17 Aug 2021.

Clinical Trials 52

Clinical Trials Events Therapy Sleep 52

MMJ Recs

DECEMBER 28, 2023

In recent years, a significant shift has occurred in the perception of medical marijuana, transforming it from a controversial substance to a recognized and, in some places, a legal form of medical treatment. Medical cannabis, with its anxiolytic properties, offers a potential solution.

Conditions 98

Conditions Chronic Pain Epilepsy Research and Development 98

The Cannigma

MARCH 7, 2022

Yet cannabinol (CBN), the first cannabinoid ever discovered by modern scientists, is slowly making a comeback in the cannabis industry. . Of course, this plant is now known to be marijuana (or Type I cannabis), which is still commonly used for sleep and analgesia today. The best online schools for medical cannabis training.

THC 140

THC Sleep Clinical Trials Cannabinoids 140

Cannabis Law Report

AUGUST 5, 2021

Psychedelics are quickly emerging as alternative methods of treatment for mental illnesses and neurodegenerative conditions — particularly in countries such as Canada. Although the overarching market is still relatively new, much like the cannabis boom a few years ago the psychedelics space is growing at an unprecedented rate.

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

AUGUST 3, 2021

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Cannabis Law Report

AUGUST 21, 2019

PUBLISHER: CANNABIS LAW REPORT. Cannabis treatments are too expensive and do not come with enough test evidence to be effective, UK authorities have said. It also said current treatments for adults suffering severe symptoms were “not cost effective”. This would answer questions about safety and efficacy, they said.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Cannabis Law Report

JUNE 21, 2021

(OTC: EHVVF) adds Dr. Jeffrey Kamlet, an expert on cardiac safety in ibogaine treatment, as Chief Medical Officer. retains CRO Sante Cannabis to conduct clinical trials in psilocybin therapies. Press Release. Entheon Biomedical Corp. CSE: ENBI) announces agreement to acquire Lobo Genetics Inc. Press Release.

Clinical Trials 66

Clinical Trials Research and Development Therapy Pharmaceutical 66

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). Orphan Drug Designation?

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

OCTOBER 13, 2021

The PCT filing also includes support for future research programs respecting various systems which seek to minimize negative side effects in psychedelic psychotherapy patients, methods that enable lower and sub-psychedelic doses without impacting treatment efficacy and increasing the long-term efficacy of psychedelic sessions. About Cybin.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

The Blunt Truth

DECEMBER 23, 2020

assured, “The FDA’s first priority is to protect the health and safety of Americans. ” Importantly, the FDA, has not approved a marketing application for cannabis for the treatment of any disease or condition and thus has not determined that cannabis is safe and effective for any particular disease or condition.

CBD 103

CBD Food Safety Clinical Trials 103

Cannabis Law Report

SEPTEMBER 22, 2021

This change would mean it would be easier to run trials on its use in mental health treatments. The Prime Minister had already approved the rescheduling of psilocybin for exploring its potential as a treatment for depression, which he informed Mr Blunt in a meeting in May.

Research and Development 52

Research and Development Clinical Trials Treatment History 52

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98